Urea Cycle

The urea cycle (also known as the ornithine cycle or the Krebs–Henseleit cycle) is a five-step cyclic biochemical pathway that converts toxic ammonium ions (NH₄⁺) generated during amino acid and nucleotide catabolism into urea ((NH₂)₂CO), an electrically neutral, non-toxic, water-soluble compound that is transported through the bloodstream to the kidneys for excretion via the nephron in urine. Discovered in 1932 by Hans Krebs and his medical student Kurt Henseleit—five years before Krebs elucidated the citric acid cycle—the urea cycle was the first cyclic metabolic pathway ever identified in biochemistry.

In humans and other ureotelic vertebrates, approximately 80% to 90% of all excreted excess nitrogen leaves the body as urea (roughly 10–30 g of urea per day depending on dietary protein intake). The complete urea cycle operates almost exclusively in the periportal hepatocytes of the liver, partitioned across two intracellular compartments: the first two enzymatic reactions take place inside the matrix of the mitochondria, while the remaining three steps occur in the cytosol. In each turn of the cycle, the two nitrogen atoms of urea are derived from two distinct metabolic donors: one nitrogen enters in the mitochondrial matrix as free ammonium (NH₄⁺) released by oxidative deamination, while the second nitrogen enters in the cytosol from the α-amino group of L-aspartate generated by transamination. Carbon is supplied by mitochondrial bicarbonate (HCO₃⁻).

Transamination, Glutamate Dehydrogenase, and Glutamine Transport

Unlike carbohydrates and lipids, excess dietary or endogenous amino acids cannot be stored in specialized polymeric depots; any amino acids surplus to protein synthesis must be catabolized. In peripheral tissues (such as skeletal muscle), pyridoxal phosphate (PLP, vitamin B₆)-dependent aminotransferases transfer the α-amino group of most amino acids onto α-ketoglutarate to form L-glutamate. To transport this nitrogen safely to the liver without elevating free blood ammonia (normal plasma [NH₄⁺] is maintained below 15–35 μM), extrahepatic tissues either convert glutamate and NH₄⁺ into neutral L-glutamine via ATP-dependent glutamine synthetase or export L-alanine via the glucose–alanine cycle. Once inside hepatic mitochondria, glutaminase hydrolyzes glutamine into glutamate + NH₄⁺, and glutamate dehydrogenase (GDH) catalyzes the oxidative deamination of glutamate into α-ketoglutarate + NH₄⁺ using NAD⁺ or NADP⁺.

Mitochondrial Reactions: CPS-I and OTC

1. Carbamoyl Phosphate Formation (Feeder Step / Step 1): In the mitochondrial matrix, carbamoyl phosphate synthetase I (CPS-I) condenses free ammonium (NH₄⁺) and bicarbonate (HCO₃⁻) at the expense of 2 molecules of ATP to synthesize the mixed anhydride carbamoyl phosphate (H₂N–CO–OPO₃²⁻). Mechanistically, the first ATP phosphorylates HCO₃⁻ to carboxyphosphate, which reacts with NH₃ to form carbamate; the second ATP phosphorylates carbamate to carbamoyl phosphate. CPS-I is the committed, rate-limiting enzyme of the urea cycle (distinct from cytosolic CPS-II, which uses glutamine for pyrimidine biosynthesis).
2. Citrulline Synthesis (Step 2): Ornithine transcarbamylase (OTC) transfers the carbamoyl group of carbamoyl phosphate onto the δ-amino group of the five-carbon non-proteinogenic amino acid L-ornithine, releasing inorganic phosphate (P_i) and forming L-citrulline. Citrulline is then transported out of the mitochondrial matrix into the cytosol in stoichiometric exchange for cytosolic ornithine by the inner-membrane ornithine/citrulline antiporter (ORNT1 / SLC25A15).

Cytosolic Reactions: ASS1, ASL, and Arginase I

1. Argininosuccinate Synthesis (Step 3): In the cytosol, argininosuccinate synthetase (ASS1) condenses the ureido oxygen of citrulline with the α-amino group of L-aspartate (the donor of the second urea nitrogen). This condensation is driven by the cleavage of ATP into AMP + pyrophosphate (PP_i) via a citrullyl-AMP intermediate, followed by exergonic hydrolysis of PP_i → 2 P_i by inorganic pyrophosphatase (representing an energetic cost equivalent to 2 ATP high-energy phosphoanhydride bonds).
2. Cleavage to Arginine and Fumarate (Step 4): Argininosuccinate lyase (ASL) catalyzes a reversible trans-elimination reaction that cleaves argininosuccinate into L-arginine (the immediate precursor of urea, retaining both nitrogen atoms) and the four-carbon dicarboxylate fumarate (which retains the carbon skeleton of aspartate).
3. Urea Hydrolysis and Ornithine Regeneration (Step 5): Cytosolic arginase I—a binuclear manganese (Mn²⁺) metalloenzyme expressed at high levels in periportal hepatocytes—hydrolyzes the guanidinium group of L-arginine to release urea and regenerate L-ornithine. Ornithine is imported back into the mitochondrial matrix via ORNT1 to initiate another turn of the cycle, while urea diffuses into the hepatic veins for renal clearance.

Integration with the Citric Acid Cycle

The fumarate released in the cytosol by argininosuccinate lyase (Step 4) is not wasted; instead, it links the urea cycle directly to the citric acid cycle in a metabolic dual-loop termed the aspartate–argininosuccinate shunt or the Krebs bicycle. Cytosolic fumarase hydrates fumarate to L-malate, which can either enter the mitochondrial matrix via the malate–α-ketoglutarate carrier or be oxidized in the cytosol. Inside the mitochondrion, malate dehydrogenase oxidizes malate to oxaloacetate, reducing NAD⁺ to NADH (which yields ~2.5 ATP via oxidative phosphorylation in the electron transport chain). Mitochondrial aspartate aminotransferase then transaminates oxaloacetate with glutamate to regenerate L-aspartate, which is exported back to the cytosol via the citrin (aspartate–glutamate) carrier to enter Step 3.

Overall Stoichiometry and Net ATP Cost

Summing the five steps of the urea cycle yields the net stoichiometric equation:

NH₄⁺ + HCO₃⁻ + L-Aspartate + 3 ATP + H₂O → Urea + Fumarate + 2 ADP + AMP + 2 P_i + PP_i

Because the cleavage of 1 ATP to AMP + PP_i (followed by PP_i → 2 P_i) consumes two high-energy phosphate bond equivalents alongside the 2 ATP → 2 ADP hydrolyzed by CPS-I, each molecule of urea synthesized requires 4 high-energy phosphate bonds. However, when coupled to the Krebs bicycle, the oxidation of fumarate → malate → oxaloacetate generates 1 mitochondrial NADH (~2.5 ATP), reducing the net bioenergetic cost of hepatic ureagenesis to approximately 1.5 ATP equivalents per urea molecule.

• Allosteric Activation by N-Acetylglutamate (NAG): Short-term flux through the urea cycle is controlled at CPS-I, which is catalytically inactive unless bound to its obligate allosteric activator, N-acetylglutamate (NAG). NAG is synthesized in the mitochondrial matrix from acetyl-CoA and glutamate by N-acetylglutamate synthase (NAGS), an enzyme that is itself allosterically stimulated by L-arginine. Following a high-protein meal, rising hepatic glutamate and arginine concentrations stimulate NAGS to produce NAG, switching on CPS-I. Over days of high protein intake or starvation, glucagon and cortisol transcriptionally upregulate all five urea cycle enzymes.
• Comparative Nitrogen Excretion: Animals employ three evolutionary strategies for nitrogen excretion depending on water availability: (1) Ammonotelic organisms (aquatic teleost fishes, crustacea, and larval amphibians such as tadpoles) excrete NH₃/NH₄⁺ directly across their gills into surrounding water, saving ATP; (2) Ureotelic organisms (terrestrial mammals, adult amphibians after thyroxine-driven metamorphosis, and marine elasmobranchs like sharks, which retain ~300–400 mM blood urea as an osmolyte) synthesize urea; and (3) Uricotelic organisms (birds, terrestrial reptiles, and insects) convert nitrogen via the purine pathway into insoluble uric acid, which precipitates as a semi-solid paste to conserve water and prevent osmotic toxicity inside cleidoic (shelled) eggs.

Why is elevated blood ammonia (hyperammonemia) acutely neurotoxic to the brain?

Uncharged ammonia (NH₃) crosses the blood–brain barrier freely and enters astrocytes, where glutamine synthetase consumes ATP to combine NH₄⁺ with glutamate to form glutamine. This reaction depletes α-ketoglutarate (impairing the neuronal citric acid cycle) and depletes the excitatory neurotransmitter glutamate, while the accumulation of osmotically active glutamine inside astrocytes drives water influx via aquaporin-4 channels, causing astrocyte swelling, cerebral edema, elevated intracranial pressure, lethargy, coma, and death.

Why is ornithine transcarbamylase (OTC) deficiency the most common urea cycle disorder?

Whereas deficiencies in CPS-I, ASS1 (citrullinemia), ASL, and arginase I are inherited as rare autosomal recessive traits, the OTC gene resides on the X chromosome (Xp11.4), making OTC deficiency an X-linked disorder (incidence ~1 in 14,000–56,000 births). Hemizygous affected males present within 24–72 hours of birth with severe hyperammonemia, respiratory alkalosis, low plasma citrulline, and elevated urinary orotic acid because accumulated mitochondrial carbamoyl phosphate spills into the cytosol and enters the pyrimidine biosynthesis pathway.

How do sodium phenylbutyrate and sodium benzoate treat urea cycle disorders?

In patients with genetic urea cycle blocks, nitrogen scavenger prodrugs bypass the defective cycle by conjugating amino acids directly for renal clearance. Sodium benzoate is activated to benzoyl-CoA and conjugated with glycine to form hippurate (excreting 1 N per benzoate), while sodium phenylbutyrate (oxidized in vivo to phenylacetate) is conjugated with glutamine to form phenylacetylglutamine (excreting 2 N per molecule in urine).

1. Krebs, H. A., & Henseleit, K. (1932). "Untersuchungen über die Harnstoffbildung im Tierkörper." Hoppe-Seyler's Zeitschrift für Physiologische Chemie, 210(1–2), 33–66. https://doi.org/10.1515/bchm2.1932.210.1-2.33
2. Morris, S. M. (2002). "Regulation of Enzymes of the Urea Cycle and Arginine Metabolism." Annual Review of Nutrition, 22(1), 87–105. https://doi.org/10.1146/annurev.nutr.22.110801.140547
3. Brusilow, S. W., & Maestri, N. E. (1996). "Urea Cycle Disorders: Diagnosis, Pathophysiology, and Therapy." Advances in Pediatrics, 43(1), 127–170. https://doi.org/10.1056/NEJM198406213102503
4. Matsumoto, S., Häberle, J., Kido, J., Mitsubuchi, H., Endo, F., & Nakamura, K. (2019). "Urea Cycle Disorders—Update on Pathophysiology, Management and Newborn Screening." Journal of Human Genetics, 64(9), 833–847. https://doi.org/10.1038/s10038-019-0614-4